Systemic Treatment of Stage IV Epithelial Ovarian Cancer; A Case Report
DOI:
https://doi.org/10.52206/jsmc.2020.10.2.%25pKeywords:
Epithelial Ovarian Cancer, Cytoreductive surgery, Adjuvant Chemotherapy, MetsAbstract
Epithelial ovarian cancer is most common gynecologic malignancy in Pakistan. Primary cytoreductive surgery followed by adjuvant chemotherapy is current standard of care for most of the patients with epithelial ovarian cancer, however neoadjuvant chemotherapy followed by surgery is acceptable alternate option for patients presenting with inoperable advanced disease initially. For most of the stage IV ovarian cancer patients, systemic chemotherapy is mainstay of treatment, but other approaches have been emerged for advanced disease including targeted agents, hormonal therapy and PARP inhibitors.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 The authors retain the copyrights. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on their website), as it can lead to productive exchanges, as well as greater citation of published work.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
